OR WAIT null SECS
Making the Grade: The Importance of Using the Correct Excipient Grade in Drug Products
With an ever-growing market driving technological advances, there is always work to be done in drug manufacturing.
Advanced oral dosage forms allow for modulation of controlled- and sustained-release profiles.
Packaging and packaging line innovations are addressing the industry’s growing use of biologics.
What are the lessons gleaned from a product’s E&L lifetime?
There are considerations companies may want to consider before seeking out a service provider.
The Biosimilars Landscape
May 11, 2024
Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.
May 10, 2024
At CPHI NA, Rachel Harris, AstraZeneca, spoke on her work at BioPhorum to enable industry consensus and action for sustainability with drug delivery devices.
May 09, 2024
Tara Dougal, content director, Pharma, Informa Markets, discusses successes and insights from this year’s CPHI North America and the agenda for the upcoming CPHI Milan.
Purna Thakker, founder and CEO of ADPT Solution, discusses common issues that companies face with FDA regulations at CPHI North America.
The company’s presentation at ASGCT includes preliminary data results for a child who received the gene therapy.
A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics.
May 08, 2024
Experiments conducted by the downstream technology team at Spark Therapeutics involving metal ion-containing additives showed improved capsid clearance in AAV production.
The company is presenting preclinical data at the American Society of Gene & Cell Therapy annual meeting that supports the potential of the company’s CAP-002 gene therapy for correcting neurological phenotypes associated with genetic epilepsy due to syntaxin-binding protein 1 (STXBP1) mutations.
This study reviews changes in in-country testing (registration testing, import testing) requirements and analyzes current trends. In the context of international harmonization of good practices and standards as well as the improved information exchange between national regulatory authorities, in-country testing is considered outdated and redundant in many cases.
May 07, 2024
ProPharm and PBL have introduced a fully automated, enclosed cell factory manufacturing device.